Reata Pharmaceuticals Inc. (NASDAQ:RETA) has received an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12 month consensus price objective of $33.00 for the company and are predicting that the company will post ($0.18) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Reata Pharmaceuticals an industry rank of 105 out of 265 based on the ratings given to its competitors.
Several research firms have commented on RETA. Piper Jaffray Cos. set a $33.00 price target on shares of Reata Pharmaceuticals and gave the company a “buy” rating in a report on Friday, October 7th. Zacks Investment Research raised shares of Reata Pharmaceuticals from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a research note on Wednesday, September 21st.
Shares of Reata Pharmaceuticals (NASDAQ:RETA) opened at 24.43 on Friday. The company’s market capitalization is $545.40 million. The firm’s 50-day moving average price is $25.31 and its 200 day moving average price is $20.51. Reata Pharmaceuticals has a 52 week low of $11.03 and a 52 week high of $32.22.
Reata Pharmaceuticals (NASDAQ:RETA) last posted its quarterly earnings results on Thursday, August 11th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.03. The business earned $12.40 million during the quarter. Equities analysts predict that Reata Pharmaceuticals will post ($0.54) EPS for the current year.
In other news, insider Colin John Meyer bought 7,000 shares of the stock in a transaction dated Tuesday, August 16th. The shares were acquired at an average cost of $16.26 per share, with a total value of $113,820.00. Following the purchase, the insider now directly owns 27,172 shares in the company, valued at approximately $441,816.72. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Jack Nielsen bought 1,780 shares of the stock in a transaction dated Monday, August 22nd. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $30,260.00. Following the completion of the purchase, the director now owns 1,780 shares in the company, valued at $30,260. The disclosure for this purchase can be found here. Insiders own 62.40% of the company’s stock.
A hedge fund recently bought a new stake in Reata Pharmaceuticals stock. Osborn Rohs Williams & Donohoe Ltd purchased a new position in shares of Reata Pharmaceuticals Inc. (NASDAQ:RETA) during the third quarter, according to its most recent 13F filing with the SEC. The fund purchased 47,000 shares of the company’s stock, valued at approximately $1,239,000. Osborn Rohs Williams & Donohoe Ltd owned about 0.21% of Reata Pharmaceuticals as of its most recent SEC filing. 69.43% of the stock is currently owned by hedge funds and other institutional investors.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.